• Nelfinavir, also called Viracept, is a drug used as part of antiretroviral therapy (ART). (thebody.com)
  • During multiple dose administration of Viracept, antiretroviral therapy will be intensified by either adding or modifying therapy. (nih.gov)
  • This is an open-label, randomized, pilot, Phase II study of the safety and efficacy of Viracept in combination with modified antiretroviral therapy as treatment in patients with cutaneous and mucosal KS. (knowcancer.com)
  • Patients will be randomized to modify (add or switch or initiate) their current antiretroviral therapy and will add Viracept or remain on their current background antiretroviral therapy for a 2 month period. (knowcancer.com)
  • Pfizer is working with the FDA to prospectively limit EMS levels in Viracept, while still considering the immediate needs of patients on therapy,' a company statement said. (medindia.net)
  • Pregnant women currently taking Viracept should be switched to an alternative medicine until the manufacturing changes are made, Pfizer said. (medindia.net)
  • For pregnant women with no alternative treatment options, 'FDA and Pfizer agree that the risk-benefit ratio remains favorable for the continued use of Viracept,' the letter said. (medindia.net)
  • Viracept is made by Pfizer, Inc. The drug is currently under the protection of patents that prevent any generic Viracept from being manufactured in the United States. (emedtv.com)
  • According to manufacturer Roche, the decision to discontinue Viracept was based on several factors, including decreasing demand and exclusion of the drug from most clinical guidelines. (mims.co.uk)
  • EMS levels in a daily dose (2,500 mg Viracept/day) were predicted not to exceed a dose of ~2.75 mg/day (~0.055 mg/kg/day based on 50 kg patient). (biomedcentral.com)
  • In August, authorities suspended Roche's license to market Viracept in the European Union because of the EMS finding. (medindia.net)
  • Pediatric patients who are stable on Viracept-containing regimens may continue to be treated with the drug, the company said. (medindia.net)
  • Initially 20 patients will be randomized in a 2:1 ratio (i.e., 14 Viracept, 6 control) for a 2 month period. (knowcancer.com)
  • At this point, patients who were initially assigned to the control arm will continue on open label Viracept for an additional 10 month period. (knowcancer.com)
  • Co-administration of Viracept with CYP3A or CYP2C19 products may alter the concentration of these products and Viracept. (aids-drugs-online.com)
  • It is important that you seek medical attention immediately if you believe that you may have overdosed on Viracept. (emedtv.com)